Technology | PET-CT | January 21, 2016

Siemens Receives FDA Clearance for Biograph Horizon PET/CT System

Versatile, scalable PET/CT system addresses broad range of indications

Siemens, Biograph Horizon PET CT, FDA clearance

January 21, 2016 — Siemens Healthcare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Biograph Horizon positron emission tomography/computed tomography (PET/CT) system, which offers premium performance at a low total cost of ownership. The system leverages proven PET/CT technology to help providers address more clinical indications in oncology, neurology and cardiology, while also introducing new efficiencies and cost savings.

Biograph Horizon enables physicians to visualize small lesions early. The system’s 4 mm LSO crystals scintillate faster and have a higher light output than BGO crystals, resulting in high resolution and better image quality, and enabling Time-of-Flight acquisition. Biograph Horizon’s capabilities are valuable for many indications, like lung cancer – the most common PET/CT indication, at 29 percent of the total exam mix. As more than half of lung cancer patients are diagnosed at a late stage and have an increased likelihood of distant metastasis, more detailed patient data can help clinicians more accurately stage disease and evaluate therapy response, contributing to more effective care pathways.

The recent decision of the U.S. Preventive Services Task Force (USPSTF) to recommend annual lung cancer screening with low-dose CT for high-risk adults has the potential to generate more suspicious findings, for which biopsies are often performed to confirm malignancy. However, 43 percent of these biopsies come back negative, and 1 in 6 result in an adverse event such as lung collapse, which can cost up to 28 times more than the cost of incorporating PET/CT into the evaluation following lung cancer screening. High-contrast, high-resolution PET/CT with Time-of-Flight can help clinicians identify additional diagnostic procedures, like biopsy, that are most appropriate for each lung cancer patient, supporting improved patient outcomes, lower procedure costs and reduced liability risks. To help providers address the growing demand for CT lung exams, Biograph Horizon also can be used as a shared service to support CT overflow, reduce patient wait times and enable scheduling flexibility.

As the smallest PET/CT system with the lowest power requirements, Biograph Horizon minimizes the initial capital investment and is a smart choice for institutions looking to replace their current PET/CT scanner, according to Siemens, as the system will fit into virtually any existing PET/CT exam room. Biograph Horizon offers low operating and maintenance costs to help manage the total cost of ownership, with automated technologies such as gentle system warm-up and automatic standby that extend the system’s economic life in addition to reducing power consumption. And Siemens’ Guardian Program predicts system issues before they occur, lowering costs related to unplanned downtime by 43 percent.

To increase productivity and time spent with patients, Biograph Horizon simplifies staff’s daily routine by automating manual tasks and offering protocol-based exams. For example, the Quanti•QC feature can run quality control procedures overnight, scans can be performed in as fast as 5 minutes, and reconstruction runs alongside acquisition for image delivery just 30 seconds after the scan.

Configured specifically for Biograph Horizon, syngo.via Molecular Imaging Workplace is a cost-effective image processing solution that can expand with providers’ clinical needs. The solution offers automated tools to instantly visualize diagnostic information, measure with confidence and report more comprehensively. syngo.via automates prefetching, preprocessing, and display and comparison of previous findings for up to 45 percent faster processing. Also, ALPHA technology provides automatic registration with organ-based recognition capabilities. EQ•PET normalizes standard uptake value (SUV) measurements across different scanners for more precise calculation of changes in tumor uptake.

For more information: www.usa.siemens.com

Related Content

Lantheus and GE Healthcare Sign Agreement for Worldwide Development, Commercialization of Flurpiridaz F-18
News | Radiopharmaceuticals and Tracers | May 22, 2017
May 22, 2017 — Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc., and GE Healthcare announced t
FALCON Trial of Fluciclovine PET/CT Imaging Stops Recruitment after Successful Interim Analysis
News | Radiopharmaceuticals and Tracers | May 15, 2017
Blue Earth Diagnostics announced that the Trial Steering Committee recommended further recruitment be stopped in the...
Study Reveals Low Adoption of IAEA Recommendations for Reduced Nuclear Cardiology Radiation Exposure
News | Radiation Dose Management | May 12, 2017
A study in 65 countries has revealed low adoption of International Atomic Energy Agency (IAEA) recommendations to...
Large Nuclear Cardiology Laboratory Slashes Radiation Dose 60 Percent in Eight Years
News | Radiation Dose Management | May 11, 2017
A large nuclear cardiology laboratory in Missouri has slashed its average radiation dose by 60 percent in eight years,...
low-dose lung CT scan

An example of a low-dose CT scan of the lungs, showing lung cancer. Image courtesy of Toshiba.

Feature | Lung Cancer | May 05, 2017 | Alison Grimes
The term mesothelioma was coined in 1909, just a few years after the introduction of medical X-ray imaging.
PET/CT

The Philips Ingenuity TF PET/CT system leverages multiple technologies.

Feature | Radiation Oncology | May 05, 2017 | By Lola Koktysh
The continuum of personalized care, covering individualized prevention and therapy, translates into multiple changes to...
Sponsored Content | Videos | Business | May 03, 2017
Kim A.
PET/CT Helps Predict Therapy Effectiveness in Pediatric Brain Tumors

FIGURE: MRI AND PET-MRI FUSION IMAGES OF PATIENTS WITH DIPG. Top row: Zr-89-bevacizumab PET (144 hrs p.i.) fused with T1-Gd weighted MRI per patient; middle row: T1-Gd weighted MRI; lower row: T2-weighted/FLAIR MR-images. Five tumors show variable uptake of Zr-89-bevacizumab (white arrows), with both PET negative and positive areas within each tumor. Two primary tumors are completely PET negative (Fig. 1C and 1E), while the T2 weighted images show tumor infiltration in the whole pons of both patients. In the middle row, the red arrows represent the areas of contrast enhancement within the tumor. In four out of five primary tumors, the PET-positive area corresponds with the contrast-enhancing area on MRI of the tumors (Fig. 1A, 1B, 1F and 1G). In Fig. 1C, the tumor shows an MRI contrast-enhancing area, while there is no Zr-89-bevacizumab uptake. Fig. 1D shows a PET positive tumor, while no Gd-enhancement is observed on MRI. Credit: Sophie Veldhuijzen van Zanten and Marc Jansen, VU University Medical Center, Amsterdam, The Netherlands.

News | PET-CT | May 02, 2017
In a first-ever molecular drug-imaging study in children, researchers in The Netherlands used whole-body positron...
Australian Team Finds New Method for Producing PET Radiotracers in Higher Radiochemical Yields
News | Radiopharmaceuticals and Tracers | April 28, 2017
April 28, 2017 — Researchers at the Australian Nuclear Science and Technology Organisation (ANSTO) have led the devel
Sponsored Content | Videos | Nuclear Imaging | April 28, 2017
David Wolinsky, M.D., director of nuclear cardiology at Cleveland Clinic Florida and past-president of the American S
Overlay Init